{
    "organizations": [],
    "uuid": "28d5d26877fb906798eca53325ac18a7470c3669",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-revance-therapeutics-mylan-ireland/brief-revance-therapeutics-mylan-ireland-enter-collaboration-deal-idUSFWN1QI1ML",
    "ord_in_thread": 0,
    "title": "BRIEF-Revance Therapeutics, Mylan Ireland Enter Collaboration Deal‍",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 28 (Reuters) - Revance Therapeutics Inc:\n* REVANCE THERAPEUTICS SAYS ‍CO, MYLAN IRELAND LIMITED ENTERED INTO COLLABORATION DEAL- SEC FILING​\n* REVANCE THERAPEUTICS - ‍MYLAN AGREED TO PAY CO NON-REFUNDABLE UPFRONT PAYMENT OF $25 MILLION WITH CONTINGENT PAYMENTS OF UP TO $100 MILLION\n* REVANCE THERAPEUTICS - ‍CONTINGENT PAYMENTS BASED UPON ACHIEVEMENT OF SPECIFIED MILESTONES, SPECIFIED, TIERED SALES MILESTONES OF UP TO $225 MILLION​\n* REVANCE THERAPEUTICS INC - ‍MYLAN WILL PAY REVANCE ROYALTIES ON SALES OF BIOSIMILAR IN MYLAN TERRITORIES​\n* REVANCE THERAPEUTICS - ‍MYLAN MAY ELECT TO HAVE DRUG PRODUCT MANUFACTURED BY ANOTHER PARTY\n* REVANCE THERAPEUTICS INC - CO GRANTED MYLAN EXCLUSIVE, LICENSE TO CO‘S INTELLECTUAL PROPERTY RIGHTS FOR DEVELOPMENT, COMMERCIALIZATION OF BIOSIMILAR​\n* REVANCE THERAPEUTICS INC - CO WILL BE PRIMARILY RESPONSIBLE FOR NON-CLINICAL DEVELOPMENT ACTIVITIES, CLINICAL DEVELOPMENT ACTIVITIES IN N. AMERICA​ Source: ( bit.ly/2EZUJWL ) Further company coverage:\n ",
    "published": "2018-03-01T05:26:00.000+02:00",
    "crawled": "2018-03-01T20:57:31.009+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "revance",
        "therapeutic",
        "inc",
        "revance",
        "therapeutic",
        "say",
        "mylan",
        "ireland",
        "limited",
        "entered",
        "collaboration",
        "sec",
        "revance",
        "therapeutic",
        "agreed",
        "pay",
        "co",
        "upfront",
        "payment",
        "million",
        "contingent",
        "payment",
        "million",
        "revance",
        "therapeutic",
        "payment",
        "based",
        "upon",
        "achievement",
        "specified",
        "milestone",
        "specified",
        "tiered",
        "sale",
        "milestone",
        "revance",
        "therapeutic",
        "inc",
        "pay",
        "revance",
        "royalty",
        "sale",
        "biosimilar",
        "mylan",
        "revance",
        "therapeutic",
        "may",
        "elect",
        "drug",
        "product",
        "manufactured",
        "another",
        "party",
        "revance",
        "therapeutic",
        "inc",
        "co",
        "granted",
        "mylan",
        "exclusive",
        "license",
        "co",
        "intellectual",
        "property",
        "right",
        "development",
        "commercialization",
        "revance",
        "therapeutic",
        "inc",
        "co",
        "primarily",
        "responsible",
        "development",
        "activity",
        "clinical",
        "development",
        "activity",
        "source",
        "company",
        "coverage"
    ]
}